Comparing two nasal oxygen cannulas in COPD flare-up patients with high carbon dioxide
Compares a new asymmetric nasal cannula with a standard one in COPD flare-ups.
Plain-language title generated from the registry record
Registry title: DUET Versus Standard Interface for Hypercapnic COPD Patients
Key facts
- Where
- Athens and Larissa, GreeceSee the 2 sites
Where in Greece
- Sotiria General HospitalAthens, GreeceTaking people
- University Hospital of LarissaLarissa, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Larissa University Hospital
- Trial code
- NCT05829083
- Record updated
- 10 September 2025
- Original description
The goal of this clinical trial is to compare the new asymmetric nasal high flow interface with the conventional high flow nasal cannula in patients with COPD exacerbation.Read full original descriptionShow less
Asymmetric (DUET) Versus Conventional Nasal High Flow Interface for Management of Hypercapnic Patients With Mild to Moderate Acute Exacerbation of COPD: A Randomized, Crossover Clinical Trial
The goal of this clinical trial is to compare the new asymmetric nasal high flow interface with the conventional high flow nasal cannula in patients with COPD exacerbation.
The main questions the study aims to answer are:
• Does the use of the asymmetric interface lead to:
1. A greater decrease in the patients' carbon dioxide 2. A greater decrease in respiratory rate and less dyspnea 3. Less need for advanced oxygen therapy measures 4. Same tolerance and comfort 5. Lower heart rate and blood pressure
Participants will be asked to:
Wear the asymmetric and conventional cannulas for 3 hours each with a 30 minute gap in-between. Arterial blood samples and various clinical parameters will be collected throughout the study period.
Researchers will compare the effect of asymmetric versus conventional cannulas to answer the aforementioned questions.
Inclusion: acute exacerbation of COPD (defined as any worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to change in medication); mild-to-moderate acute hypercapnic respiratory failure (defined as 7.35>pH>7.25 and arterial CO2 tension (PaCO2) >45 mmHg).
Exclusion: severe haemodynamic instability unresponsive to fluids and vasoactive drugs; acute on chronic hypercapnic respiratory failure; indication for imminent intubation and invasive mechanical ventilation (i.e. respiratory or cardiac arrest, diminished consciousness (Glasgow coma score <8); severe ventricular or supraventricular arrhythmias; severe facial deformity, facial burns, fixed upper airway obstruction; psychomotor agitation inadequately controlled by sedation; massive aspiration; persistent inability to remove respiratory secretions; life threatening hypoxaemia.